Less Ads, More Data, More Tools Register for FREE

Pin to quick picksASP.L Regulatory News (ASP)

  • There is currently no data for ASP

Directorate Change

16 Jul 2007 07:00

Ascribe plc16 July 2007 Press Release 16 July 2007 Ascribe plc ("Ascribe" or "the Group") Non-Executive Director Appointment Ascribe plc (AIM:ASP), the health IT Group, announces that Ian Priestner hasbeen appointed to the Board as an independent Non-Executive Director, withimmediate effect. Ian (50) is currently a Non-Executive Director of the Walton Centre forNeurology and Neurosurgery NHS Trust. During the last ten years, Ian has workedas Head of Public Policy and Government Relations (UK and International) forBritish Gas plc (holding brand for Transco and BG Group), and was Group Directorof Corporate Communications for United Utilities PLC where he was a member ofthe Executive Leadership Team from 2000 to 2006. In 1979, Ian worked for the Confederation of British Industry in itsInternational Affairs department and later moved to become the Public AffairsSpecialist for the United States Embassy in London. In 1986, Ian became ChiefPress Officer for the Social Democratic Party. He later became a CommunicationsConsultant for Lowe Bell and Public Affairs Manager for Conoco (UK) Ltd. Ianholds degrees in International Relations and Law. David Hughes, currently a Non-Executive Director of Ascribe with four yearsservice, will move to the role of Non-Executive Deputy Chairman and also chairthe Audit and Remuneration Committees. Commenting on the appointments Stephen Critchlow, Executive Chairman of Ascribeplc, said: "We are delighted that Ian is joining the Board of Ascribe. His strongbackground in both government relations and healthcare will be a valuable assetto the Group as we expand our capability and market. Together with DavidHughes, we have a strong Non-Executive team." There is nothing further to disclose in relation to Ian Priestner's appointmentunder Schedule 2, paragraph (g) of the AIM Rules. - Ends - For further information:Ascribe plcStephen Critchlow, Executive Chairman Tel: +44 (0) 870 053 4545Jeremy Lee, Group Finance Director www.ascribe.com Cenkos Securities plcIan Soanes, Corporate Finance Tel: +44 (0) 20 7397 8900isoanes@cenkos.com www.cenkos.com Media enquiries:AbchurchHelen Spivey / Stephanie Cuthbert Tel: +44 (0) 20 7398 7700helen.spivey@abchurch-group.com www.abchurch-group.com Notes to editors Ascribe plc is a leading healthcare company that develops and markets softwaresolutions supporting patient, clinical and business processes to Primary &Secondary healthcare providers in the UK and overseas. Ascribe is committed to providing technologies that improve patient safetystandards and the Company's solutions directly improve patient care and deliverfinancial savings to customers. The Group sells directly to hospitals andPrimary Care Trusts rather than through centrally driven political initiatives. The Group provides solutions to clinical professionals in all healthcaresectors; customers include Emergency and Minor Injuries Units, Mental Health andSocial Care Units, Hospitals requiring patient administration systems (PAS) andmedical equipment management, Hospital and Retail Pharmacies, and GeneralPractice surgeries. Offering patient and decision support information to theseclinicians in context with their activity is the key to the Company's ongoingsuccess. Ascribe plc was floated on AIM in 2004, and currently employs over 200 personnelthrough its operating companies in the UK, Kenya, Australia and New Zealand. Formore information, please visit www.ascribe.com. (c) Ascribe 2007. Ascribe is a registered trademark of Ascribe plc. All otherbrands and product names and trademarks are the registered property of theirrespective companies. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jun 20219:49 amRNSUpdate on TIDM Code
1st Jun 20217:00 amRNSAdmission to Main Market
27th Jan 200911:45 amRNSPosting of re-registration circular
21st Jan 20097:30 amRNSOffer Unconditional in all Respects
8th Jan 20097:00 amRNSOffer update
7th Jan 20091:14 pmRNSHolding(s) in Company
5th Jan 20096:08 pmRNSGeneral Meeting & Recommended Cash Offer
18th Dec 20083:55 pmRNSAnnual Report and Accounts
17th Dec 20088:00 amRNSRecommended Cash Offer
10th Dec 200812:42 pmRNSResult of AGM
17th Nov 20087:00 amRNSDirector/PDMR Shareholding
10th Oct 200810:45 amRNSRule 8.3- Ascribe PLC
3rd Oct 200812:09 pmRNSRule 8.3- Ascribe PLC
1st Oct 20087:00 amRNSFinal Results
26th Sep 20087:00 amRNSAcquisition
3rd Sep 20089:06 amRNSExercise of Options
21st Aug 200811:39 amRNSRule 8.3- Ascribe Plc
19th Aug 20088:19 amRNSAnnouncement regarding possib
22nd Jul 20087:00 amRNSTrading Update
8th May 20087:01 amRNSASCC Framework Agreement
14th Apr 20084:29 pmRNSHolding(s) in Company
2nd Apr 20088:00 amRNSInstallement of Web Pharmacy
12th Mar 20087:01 amRNSInterim Results
15th Feb 20082:55 pmRNSIssue of Equity
4th Feb 20089:57 amRNSIssue of Equity
23rd Jan 20087:01 amRNSTrading Statement
21st Jan 20084:54 pmRNSIssue of Equity
7th Dec 200711:23 amRNSHolding(s) in Company
6th Dec 20075:28 pmRNSHolding(s) in Company
29th Nov 200711:29 amRNSDirector/PDMR Shareholding
31st Oct 200711:23 amRNSTrading update &Result of AGM
29th Oct 20073:24 pmRNSHolding(s) in Company
26th Oct 200711:29 amRNSHolding(s) in Company
25th Oct 20074:06 pmRNSDirector/PDMR Shareholding
25th Oct 200711:31 amRNSIssue of Equity
22nd Oct 20071:35 pmRNSIssue of Equity
22nd Oct 200712:40 pmRNSAcquisition
5th Oct 20079:09 amRNSHolding(s) in Company
25th Sep 20072:50 pmRNSHolding(s) in Company
19th Sep 20077:01 amRNSFinal Results
4th Sep 20077:00 amRNSNotice of Results
17th Aug 20075:30 pmRNSAIM Rule 26
17th Aug 20074:53 pmRNSAIM Rule 26 Information
15th Aug 20072:00 pmRNSHolding(s) in Company
9th Aug 20075:57 pmRNSHolding(s) in Company
30th Jul 20072:40 pmRNSIssue of Equity
24th Jul 20077:00 amRNSTrading Update
16th Jul 20075:19 pmRNSHolding(s) in Company
16th Jul 20077:00 amRNSDirectorate Change
8th Jun 20072:56 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.